CLOs on the Move

Capstone Development Services,

www.capstonedevservices.com

 
Capstone Development Services is a shared services development company focused on complex generic pharmaceuticals and medical devices. Capstone leads development, manages regulatory services, and achieves timely approval of healthcare products through ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Stacie Switzer
Chief Legal Officer Profile

Similar Companies

KCR

KCR is a clinical development solutions provider for the biotechnology, pharmaceutical, and medical device industries. We support clients with full-service clinical development capabilities across three main areas: Trial Execution, Consulting and Placement. KCR operates across four main regions: North America, Western Europe, Central Europe, and Eastern Europe, with a main operational hub located in Boston, MA. Our strategic hub locations, technical capabilities and solution offerings allow for the optimized delivery of trial execution strategies to develop life-changing therapies. KCR offers access to an estimated population of 1.1 Billion people.

Deltanoid Pharmaceuticals

Deltanoid Pharmaceuticals, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Next Generation Clinical Research Consulting

Next Generation Clinical Research Consulting is a Oregon, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blaine Labs

Blaine Labs is a Santa Fe Springs, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.